Categories: News

Avantor® to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

RADNOR, Pa., May 19, 2021 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. Michael Stubblefield, President and CEO at Avantor, will represent Avantor in the segment beginning at approximately 9:40 a.m. Eastern Daylight Time

A live webcast may be accessed through the investor relations section of Avantor’s website at https://ir.avantorsciences.com/investors/news-and-events/ and will be available for replay through June 30, 2021.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com.

Media Contact
Allison Hosak
Senior Vice President, Global Communications and Brand
Avantor
908-329-7281
Allison.Hosak@Avantorsciences.com

Investor Relations Contact
Tommy J. Thomas, CPA
Vice President, Investor Relations
Avantor
781-375-8051
Tommy.Thomas@Avantorsciences.com

View original content:http://www.prnewswire.com/news-releases/avantor-to-present-at-goldman-sachs-42nd-annual-global-healthcare-conference-301295213.html

SOURCE Avantor and Financial News

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

5 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago